Comparative proteome analysis of acute myeloid leukemia with and without maturation.

M. Luczak,M. Kaźmierczak,L. Handschuh,K. Lewandowski,M. Komarnicki,M. Figlerowicz

DOI: https://doi.org/10.1016/j.jprot.2012.07.030

IF: 3.855

2012-10-22

Journal of Proteomics

Abstract:

What problem does this paper attempt to address?

[Analysis of Age-Specific Cytogenetic Changes among 515 Patients Withacute Myeloid Leukemia].

Lin Liu,Huan Xu,Zhimei Chen,Jiyu Lou,Huanping Wang,Jie Jin

DOI: https://doi.org/10.3760/cma.j.issn.1003-9406.2019.06.005

2019-01-01

Abstract:OBJECTIVE To characterize cytogenetic changes and prognosis of patients with acute myeloid leukemia (AML) from different age groups. METHODS The karyotypes of 515 AML patients were analyzed by using short-term culture of bone marrow cells and R-banding technique. Combined with FAB typing and genetic testing, cytogenetic changes and prognosis of different age groups were analyzed. RESULTS The abnormal cloning rate was 54.6% among the 515 patients. The abnormal cloning rate and adverse risk karyotype proportion of those with myeloproliferative syndromes (MDS) and secondary AML were higher than those with de novo AML (P = 0.027; P<0.01). A significant difference was found in the number of structural abnormalities and proportion of favorable risk karyotypes among different age groups (P = 0.026; P = 0.004). And there was also a significant difference in the abnormal cloning rate between different FAB types (P<0.01). In those with non-acute promyelocytic leukemia (APL), the expression level of WT1 gene seemed to affect the prognosis. The survival rate of patients with karyotypes of adverse risk was lower than those with karyotypes of favorable risk (P = 0.015). The survival rate of the ≥60-year-old group was lower than the ≤30-year-old and 31 to 59-year-old groups (P<0.01, P<0.01). CONCLUSION The karyotypes of AML patients have different age distribution characteristics. The survival rate of ≥60-years-old group and karyotype of poor prognosis is low. Patients with MDS with secondary AML have a poor prognosis.
Aging and Comprehensive Molecular Profiling in Acute Myeloid Leukemia.

Jian-Feng Li,Wen-Yan Cheng,Xiang-Jie Lin,Li-Jun Wen,Kai Wang,Yong-Mei Zhu,Hong-Ming Zhu,Xin-Jie Chen,Yu-Liang Zhang,Wei Yin,Jia-Nan Zhang,Xiao Yi,Fan Zhang,Xiang-Qin Weng,Sheng-Yue Wang,Lu Jiang,Hui-Yi Wu,Jia-Qi Ren,Xiao-Jing Lin,Niu Qiao,Yu-Ting Dai,Hai Fang,Yun Tan,Xiao-Jian Sun,Gang Lv,Xiao-Yu Yan,Su-Ning Chen,Zhu Chen,Jie Jin,De-Pei Wu,Rui-Bao Ren,Sai-Juan Chen,Yang Shen

DOI: https://doi.org/10.1073/pnas.2319366121

2024-01-01

Abstract:Acute myeloid leukemia (AML) is an aging-related and heterogeneous hematopoietic malignancy. In this study, a total of 1,474 newly diagnosed AML patients with RNA sequencing data were enrolled, and targeted or whole exome sequencing data were obtained in 94% cases. The correlation of aging-related factors including age and clonal hematopoiesis (CH), gender, and genomic/transcriptomic profiles (gene fusions, genetic mutations, and gene expression networks or pathways) was systematically analyzed. Overall, AML patients aged 60 y and older showed an apparently dismal prognosis. Alongside age, the frequency of gene fusions defined in the World Health Organization classification decreased, while the positive rate of gene mutations, especially CH-related ones, increased. Additionally, the number of genetic mutations was higher in gene fusion-negative (GF-) patients than those with GF. Based on the status of CH- and myelodysplastic syndromes (MDS)-related mutations, three mutant subgroups were identified among the GF- AML cohort, namely, CH-AML, CH-MDS-AML, and other GF- AML. Notably, CH-MDS-AML demonstrated a predominance of elderly and male cases, cytopenia, and significantly adverse clinical outcomes. Besides, gene expression networks including HOXA/B, platelet factors, and inflammatory responses were most striking features associated with aging and poor prognosis in AML. Our work has thus unraveled the intricate regulatory circuitry of interactions among different age, gender, and molecular groups of AML.
MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Zejuan Li,Jun Lu,Miao Sun,Shuangli Mi,Hao Zhang,Roger T. Luo,Zhijian Qian,Mary Beth Neilly,Yungui Wang,Jie Jin,Yanming Zhang,Stefan K. Bohlander,Richard Larson,Michelle LeBeau,Michael J. Thirman,Todd R. Golub,Janet D. Rowley,Jianjun Chen

DOI: https://doi.org/10.1182/blood.v110.11.3181.3181

IF: 20.3

2007-01-01

Blood

Abstract:Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. It is estimated that 13,410 cases will be diagnosed and 8,990 will die of AML in the United States in 2007 (http://seer.cancer.gov). AML is a genetically diverse hematopoietic malignancy with variable response to treatment. Expression profiling of protein-coding genes using DNA microarray in AML has resulted in inconsistent data from different laboratories. Therefore, further validation of these observations in large cohorts and in independent studies is definitely required before clinical application becomes feasible. Recently, Golub and colleagues described a new, bead-based flow cytometric microRNA (miRNAs, miRs) expression profiling method that could successfully classify tumors. MiRNAs are endogenous ∼22 nucleotide non-coding RNAs, which can function as oncogenes and tumor suppressors. To provide new insights into the complex genetic alterations in leukemogenesis and to identify novel markers for diagnosis and treatment of AML, we performed a genome-wide analysis of miRNA expression profiles using the bead-based method on 54 AML samples with common translocations including t(15;17), t(8;21), inv(16), and 11q23 rearrangement, along with normal controls. In both unsupervised and supervised hierarchical cluster analyses, we observed that t(15;17) samples grouped together as one cluster, as do the 11q23 rearrangement samples. Interestingly, t(8;21) and inv(16), both CBF (core-binding factor) AMLs, grouped together as a unique cluster. Forty-one miRNAs exhibited significantly differential expression between different subtypes of AMLs, and/or between AMLs and normal controls. Notably, expression signature of a minimal number of two, three, and seven miRNAs could be used for class prediction of CBF, t(15;17), and 11q23 rearrangement AMLs, respectively, with an overall diagnostic accuracy of 94–96%. We further showed that overexpression of the two discriminatory miRNAs in CBF AML is associated with epigenetic regulation, rather than DNA copy number amplification. Moreover, several important target genes of these discriminatory miRNAs have also been validated. We are currently exploring the role of these discriminatory miRNAs and their critical target genes in the development of AML using in vitro and in vivo models. This work will enhance our understanding of the biological role of these miRNAs and their targets in leukemogenesis.
Clinical and Biological Characteristics of Acute Myeloid Leukemia with 20-29% Blasts: a Retrospective Single-Center Study

Chen Mei,Yanling Ren,Xinping Zhou,Li Ye,Liya Ma,Yingwan Luo,Peipei Lin,Weilai Xu,Chenxi Lu,Haiyang Yang,Wenjuan Yu,Liping Mao,Juying Wei,Jie Jin,Hongyan Tong

DOI: https://doi.org/10.1080/10428194.2018.1515938

2018-01-01

Abstract:It is controversial whether acute myeloid leukemia (AML) patients with 20-29% bone marrow (BM) blasts should be considered AML or myelodysplastic syndromes (MDS). We retrospectively studied 382 patients, including 108 AML with 20-29% BM blasts (AML20-29), 210 AML with >= 30% BM blasts (AML >= 30), and 64 MDS with 10-19% BM blasts (MDS-EB2). We found that AML20-29 were more similar to MDS-EB2 in terms of advanced age, less blood count, the increased presence of poor-risk cytogenetics. The frequency of mutated genes in AML20-29 had both the characters of AML and MDS. Median overall survival of AML20-29 and MDS-EB2 were similar and shorter than those of AML >= 30 (p = .045). Multivariate analysis showed inferior survival with increased age, low platelet count and FLT3 mutations. Our findings suggest that AML20-29 have clinical features more similar to MDS than AML.
Clinical Characterization and Prognostic Factors of 144 Adult Acute Monocytic Leukemia

Yingying Wu,Xiujin Ye,Li,Jingjing Zhu,Wanzhuo Xie,Jie Zhang,Jingsong He,Zhen Cai,He Huang

DOI: https://doi.org/10.1182/blood.v120.21.4798.4798

IF: 20.3

2012-01-01

Blood

Abstract:Abstract Abstract 4798 Background: Acute monocytic leukemia (M5) is one kind of acute leukemia with poor prognosis, which has the characterization of high number of white blood cells, high risk of extramedullary metastasis and abnormal chromosome karyotype. Objective: To analyze clinical characterization and prognostic factors of adult acute monocytic leukemia. Methods: Clinical data of 144 patients diagnosed between Jan 1st 2006 and Dec 31 2010 were collected. Clinical manifestation, cytogenetics, immunophenotyping and minimal residual disease (MRD) were analyzed respectively. The numeration data was tested by χ2 test, while the measurement data by Levene test to variance homogeneity and by T test to the mean difference. The data were analyzed by SPSS 17.0. Results: 81.9% of 144 patients reached complete remission. 27.5% patients were abnormal in cytogenetics, including +8, −5/del (5q), −7/del (7q). Patients were divided into three groups according to chromosome karyotype. Intermediate prognostic group has better OS and DFS than poor prognostic group (P<0.05). 26 patients treated with SCT.These patients have higher OS rate for one year and low relapse rate than those who did not receive SCT.CR rate for old patients(≥55) and young patients (<55) were 69.4% and 86.1% respectively. Old patients had shorter OS and DFS than young patients, but no singnificant difference in FAB type, number of white blood cell and immunophenotyping. Old patients occur chromosome abnormalities more frequently than young patients. Relapse rate is 20.7% in MRD+ group versus 11.5% in MRD- group. Multivariate COX analysis showed that chromosome karyotype and MRD had most significant correlation with relapse. Conclusion: Chromosome karyotype, age, therapy, MRD were all prognostic factors of M5. Chromosome karyotype and MRD had most important significance in prognosis. Disclosures: No relevant conflicts of interest to declare.
Proteomic Analysis of Human Acute Leukemia Cells

JW Cui,J Wang,K He,BF Jin,HX Wang,W Li,LH Kang,MR Hu,HY Li,M Yu,BF Shen,GJ Wang,XM Zhang

DOI: https://doi.org/10.1158/1078-0432.ccr-04-0307

IF: 13.801

2004-01-01

Clinical Cancer Research

Abstract:Purpose: French-American-British (FAB) classification of acute leukemia with genetic heterogeneity is important for treatment and prognosis. However, the distinct protein profiles that contribute to the subtypes and facilitate molecular definition of acute leukemia classification are still unclear.Experimental Design: The proteins of leukemic cells from 61 cases of acute leukemia characterized by FAB classification were separated by two-dimensional electrophoresis, and the differentially expressed protein spots were identified by both matrix-assisted laser desorption/ionization-time-of-flight-mass spectrometry (MALDI-TOF-MS) and tandem electrospray ionization MS (ESI-MS/MS).Results: The distinct protein profiles of acute leukemia FAB types or subtypes were successfully explored, including acute myeloid leukemia (AML), its subtypes (M2, M3, and M5) and acute lymphoid leukemia (ALL), which were homogeneous within substantial samples of the respective subgroups but clearly differed from all other subgroups. We found a group of proteins that were highly expressed in M2 and M3, rather than other subtypes. Among them, myeloid-related proteins 8 and 14 were first reported to mark AML differentiation and to differentiate AML from ALL. Heat shock 27 kDa protein 1 and other proteins that are highly expressed in ALL may play important roles in clinically distinguishing AML from ALL. Another set of proteins up-regulated was restricted to granulocytic lineage leukemia. High-level expression of NM23-H1 was found in all but the M3a subtype, with favorable prognosis.Conclusions: These data have implications in delineating the pathways of aberrant gene expression underlying the pathogenesis of acute leukemia and could facilitate molecular definition of FAB classification. The extension of the present analysis to currently less well-defined acute leukemias will identify additional subgroups.
Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy

Lukasz Bolkun,Tomasz Pienkowski,Julia Sieminska,Joanna Godzien,Karolina Pietrowska,Janusz Kłoczko,Agnieszka Wierzbowska,Marcin Moniuszko,Mariusz Ratajczak,Adam Kretowski,Michal Ciborowski

DOI: https://doi.org/10.1038/s41598-023-48970-0

2023-12-09

Abstract:The heterogeneity of acute myeloid leukemia (AML), a complex hematological malignancy, is caused by mutations in myeloid cells affecting their differentiation and proliferation. Thus, various cytogenetic alterations in AML cells may be characterized by a unique metabolome and require different treatment approaches. In this study, we performed untargeted metabolomics to assess metabolomics differences between AML patients and healthy controls, AML patients with different treatment outcomes, AML patients in different risk groups based on the 2017 European LeukemiaNet (ELN) recommendations for the diagnosis and management of AML, AML patients with and without FLT3-ITD mutation, and a comparison between patients with FLT3-ITD, CBF-AML (Core binding factor acute myelogenous leukemia), and MLL AML (mixed-lineage leukemia gene) in comparison to control subjects. Analyses were performed in serum samples using liquid chromatography coupled with mass spectrometry (LC-MS). The obtained metabolomics profiles exhibited many alterations in glycerophospholipid and sphingolipid metabolism and allowed us to propose biomarkers based on each of the above assessments as an aid for diagnosis and eventual classification, allowing physicians to choose the best-suited treatment approach. These results highlight the application of LC-MS-based metabolomics of serum samples as an aid in diagnostics and a potential minimally invasive prognostic tool for identifying various cytogenetic and treatment outcomes of AML.
Analysis of the Proteomes of Primary, De Novo Acute Myeloid Leukemia Cells from Adults

Michael H Kramer,Qiang Zhang,Robert W. Sprung,Petra Erdmann-Gilmore,Daniel R George,Nichole M Helton,Sharon E Heath,Jacqueline E. Payton,Peter Westervelt,Christopher A Miller,Matthew J. Walter,Daniel C. Link,John F. DiPersio,R Reid Townsend,Timothy J Ley

DOI: https://doi.org/10.1182/blood-2021-148819

IF: 20.3

2021-11-05

Blood

Abstract:Abstract Introduction: Proteins, despite being the primary effectors of cellular processes, are often studied only indirectly through analysis of the transcriptome. However, it is clear that the relationship between mRNA expression and protein expression is approximate at best. In Acute Myeloid Leukemia (AML), the genome and transcriptome have been thoroughly characterized, but the proteome has been less well studied. Here, we present a deep-scale study of the proteomes of 44 primary AML bone marrow samples representing a wide range of AML across the spectrum of cytogenetic risk, common mutations, and driver fusions. Methods: Bone marrow samples were collected at presentation from 44 adult patients with de novo AML as part of an institutional banking protocol, and buffy coat cells were immediately cryopreserved without further manipulation. Cryovials were thawed in the presence of the cell permeable serine protease inhibitor diisopropyl fluorophosphate (DFP) to inactivate the abundant neutrophil serine proteases (ELANE, CTSG, PRTN3, and PRSS57), and further processed for nano-liquid chromatography mass spectrometry in the presence of an extensive cocktail of protease inhibitors. Both label-free quantification (LFQ) and tandem-mass-tag (TMT) deep-scale proteomics were performed on these 44 patient samples, as well as 3 lineage-depleted bone marrow samples from healthy adult donors. Matching RNA-seq and exome sequencing data were available for the same samples as part of The Cancer Genome Atlas (TCGA) AML project. Results: 10,651 and 6,679 unique proteins were detected in the TMT and LFQ experiments, respectively. Correlations between measurements derived from the independent proteomic platforms (i.e. TMT and LFQ) is higher (mean Spearman correlation, 0.60, Figure 1A) than correlation between proteomic (TMT) and transcriptomic measurements from bulk RNA-seq data (Spearman 0.43, Figure 1B). Quality checks of the proteomic data strongly supported the reliability of quantification of protein measurements; for example, the mean ratio of beta globin protein (HBB) to alpha globin (HBA1) was 1.2 +/- 0.25 (Figure 1C), and several proteins known to be dysregulated by specific AML-initiating fusion proteins (for PML-RARA, HGF and RARA; for RUNX1-RUNX1T1, RUNX1T1; and for CBFB-MYH11, MYH11) were detected in the expected samples (Figure 1D). Globally, 1,364 proteins were differentially expressed in the AML samples (corrected p-value <0.05, fold change ≥ 1.5) compared to the lineage-depleted, healthy bone marrow samples. Globally overexpressed proteins were enriched for ribosomal RNA modification, mitochondrial protein import, nuclear export, and the mitochondrial electron transport chain, among others. These overexpressed proteins include 61 cell surface proteins that could potentially represent therapeutic targets (overexpressed on average in 82% of AML samples, range 25-97%). Globally downregulated proteins in AML samples were enriched for glycogen metabolism and protein groups associated with mature neutrophils (reflecting the expected maturation block in AML), among others. 771 of the 1364 differentially expressed proteins (56.5%) showed only minimal variability in mRNA expression levels (fold change of <1.1 between AML and normal marrow CD34 cell mRNA) that could not explain dysregulated protein expression. Several protein complexes likewise showed coordinated differential expression in the proteomic data, but no change in the transcriptome, including the THO complex (Figure 1E) and the phosphorylase kinase complex (Figure 1F), among others, indicating the presence of posttranscriptional regulation of the levels of many proteins in AML samples. Conclusion: We have created a deep-scale proteomic database from a set of well-characterized AML samples, allowing for a proteogenomic study of AML. We have identified many examples of post-transcriptional regulation of key metabolic pathways that may be relevant for better understanding AML cell metabolism and therapeutic vulnerabilities. Additional studies linking patterns of protein dysregulation with a variety of AML covariates are underway. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.

hematology
Proteomic and phosphoproteomic landscapes of acute myeloid leukemia

Qiang Zhang,Robert Sprung,Petra Erdmann-Gilmore,Yang Li,Ziheng Xu,Yiling Mi,Peter Westervelt,John F. DiPersio,Michael H. Kramer,Ryan B. Day,Nichole M. Helton,Daniel R. George,Jacqueline E. Payton,Sai M. Ramakrishnan,Christopher A. Miller,Daniel C. Link,Matthew J. Walter,R. Reid Townsend,Timothy J. Ley

DOI: https://doi.org/10.1182/blood.2022016033

IF: 20.3

2022-09-29

Blood

Abstract:We have developed a deep-scale proteome and phosphoproteome database from 44 representative acute myeloid leukemia (AML) patients from the LAML TCGA dataset and 6 healthy bone marrow–derived controls. After confirming data quality, we orthogonally validated several previously undescribed features of AML revealed by the proteomic data. We identified examples of posttranscriptionally regulated proteins both globally (ie, in all AML samples) and also in patients with recurrent AML driver mutations. For example, samples with IDH1/2 mutations displayed elevated levels of the 2-oxoglutarate–dependent histone demethylases KDM4A/B/C, despite no changes in messenger RNA levels for these genes; we confirmed this finding in vitro. In samples with NPMc mutations, we identified several nuclear importins with posttranscriptionally increased protein abundance and showed that they interact with NPMc but not wild-type NPM1. We identified 2 cell surface proteins (CD180 and MRC1/CD206) expressed on AML blasts of many patients (but not healthy CD34+ stem/progenitor cells) that could represent novel targets for immunologic therapies and confirmed these targets via flow cytometry. Finally, we detected nearly 30 000 phosphosites in these samples; globally, AML samples were associated with the abnormal phosphorylation of specific residues in PTPN11, STAT3, AKT1, and PRKCD. FLT3-TKD samples were associated with increased phosphorylation of activating tyrosines on the cytoplasmic Src-family tyrosine kinases FGR and HCK and related signaling proteins. PML-RARA–initiated AML samples displayed a unique phosphorylation signature, and TP53-mutant samples showed abundant phosphorylation of serine-183 on TP53 itself. This publicly available database will serve as a foundation for further investigations of protein dysregulation in AML pathogenesis.

hematology
Abstract 7354: Proteogenomic and metabolomic characterization of acute myeloid leukemia

Alec Chu,Yi Hsiao,Yamei Deng,Chenwei Wang,Jennifer Kyle,Yongchao Dou,James C. Pino,Camilo Posso,Leanne Henry,Lijun Chen,Ginny Xiaohe Li,Tung-Shing Mamie Lih,Yifat Geffen,Fengchao Yu,Li Ding,Gil Omenn,Chandan Kumar,Saravana M. Dhanasekaran,Elie Traer,Jeffrey W. Tyner,Hui Zhang,Tao Liu,Sara Gosline,Bing Zhang,Arul Chinnaiyan,Alexey I. Nesvizhskii,Marcin Cieslik,The CPTAC Consortium

DOI: https://doi.org/10.1158/1538-7445.am2024-7354

IF: 11.2

2024-03-28

Cancer Research

Abstract:Acute myeloid leukemia (AML) is a blood malignancy of poor prognosis with marked heterogeneity. To elucidate the underlying mechanisms that drive AML as part of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) effort, we performed comprehensive genomics, transcriptomics, proteomics including multiple post-translational modifications (phosphorylation, acetylation, and glycosylation), metabolomics, and lipidomics characterization of 173 treatment-naïve AML patients. Applying the similarity network fusion method on both transcriptomics and proteomics data, we identified 8 proteogenomic clusters. These clusters recapitulate specific recurrent mutations and established clinical subtypes available within the cohort. We used single-cell RNAseq data as a reference to perform immune component analysis for collected bulk samples. The result reveals that our proteogenomic clustering also captures the variations of AML differentiation hierarchies including CD14+ monocyte-like and GMP-like AML. To assess the complex disease nature of AML, we performed functional analysis for each cluster to reveal interplay between multiple genomic aberrations such as NPM1, FLT3-ITD, DNMT3A mutations, complex chromosomal alterations, and the leukemia cell differentiation. Importantly, the multi-omics analysis performed not only connects previously identified molecular drivers and cell differentiation variations within AML, but also links them with observed cancer metabolomic reprogramming with their drug response implications. Moreover, our study also identified site-specific post-translational modifications previously not known in AML, highlighting the valuable insights and clinical relevance of these newly identified clusters. Citation Format: Alec Chu, Yi Hsiao, Yamei Deng, Chenwei Wang, Jennifer Kyle, Yongchao Dou, James C. Pino, Camilo Posso, Leanne Henry, Lijun Chen, Ginny Xiaohe Li, Tung-Shing Mamie Lih, Yifat Geffen, Fengchao Yu, Li Ding, Gil Omenn, Chandan Kumar, Saravana M. Dhanasekaran, Elie Traer, Jeffrey W. Tyner, Hui Zhang, Tao Liu, Sara Gosline, Bing Zhang, Arul Chinnaiyan, Alexey I. Nesvizhskii, Marcin Cieslik, The CPTAC Consortium. Proteogenomic and metabolomic characterization of acute myeloid leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 7354.

oncology
Abstract P27: Proteogenomic and metabolomic analysis of acute myeloid leukemia reveals molecular and functional underpinnings of cellular and clinical phenotypes

Shih-Chun Alec Chu,Yi Hsiao,Yamei Deng,Chenwei Wang,Jennifer Kyle,Yongchao Dou,James Pino,Camilo Posso,Leanne Henry,Ginny Li,Li Ding,Lijun Chen,Mamie Lih,Yifat Geffen,Gilbert Omenn,Chandan Kumar,Saravana Dhanasekaran,Fengchao Yu,Elie Traer,Jeffrey W. Tyner,Hui Zhang,Tao Liu,Sara Gosline,Bing Zhang,Arul Chinnaiyan,Alexey I Nesvizhskii,Marcin Cieslik

DOI: https://doi.org/10.1158/2643-3249.bcdsymp24-p27

2024-03-05

Blood Cancer Discovery

Abstract:Acute myeloid leukemia (AML) is a blood malignancy of poor prognosis with marked heterogeneity. To elucidate the underlying mechanisms that drive AML as part of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) effort, we performed large scale comprehensive genomics, transcriptomics, proteomics including multiple post-translational modifications (phosphorylation, acetylation, and glycosylation), metabolomics, and lipidomics characterization of 173 treatment-naïve AML patients. Applying the similarity network fusion method on both transcriptomics and proteomics data, we identified 8 proteogenomic clusters. These clusters recapitulate specific recurrent mutations, fusions, structural variants, and established clinical subtypes available within the cohort, as well as reveal new cluster-specific phenotypes within other multi-omic datasets. We used single-cell RNAseq data as a reference to perform immune component analysis for collected bulk samples. The result reveals that our proteogenomic clustering also captures the variations of AML differentiation hierarchies including CD14+ monocyte-like and GMP-like AML. To assess the complex disease nature of AML, we performed functional analysis for each cluster to reveal interplay between multiple genomic aberrations such as NPM1, FLT3-ITD, DNMT3A mutations, complex chromosomal alterations, and the leukemia cell differentiation. Additionally, the multi-omics analysis performed not only connects previously identified molecular drivers and cell differentiation variations within AML, but also links them with observed cancer metabolomic reprogramming alongside differences in MTOR signaling, MYC activities, mitochondrial activities, and drug responses. Moreover, our study also identified site-specific post-translational modifications previously not known in AML, highlighting the valuable insights and clinical relevance of these newly identified clusters. Citation Format: Shih-Chun Alec Chu, Yi Hsiao, Yamei Deng, Chenwei Wang, Jennifer Kyle, Yongchao Dou, James Pino, Camilo Posso, Leanne Henry, Ginny Li, Li Ding, Lijun Chen, Mamie Lih, Yifat Geffen, Gilbert Omenn, Chandan Kumar, Saravana Dhanasekaran, Fengchao Yu, Elie Traer, Jeffrey W. Tyner, Hui Zhang, Tao Liu, Sara Gosline, Bing Zhang, Arul Chinnaiyan, Alexey I Nesvizhskii, Marcin Cieslik. Proteogenomic and metabolomic analysis of acute myeloid leukemia reveals molecular and functional underpinnings of cellular and clinical phenotypes [abstract]. In: Proceedings of the Blood Cancer Discovery Symposium; 2024 Mar 4-6; Boston, MA. Philadelphia (PA): AACR; Blood Cancer Discov 2024;5(2_Suppl) nr P27.

English Else
A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations

Frode Selheim,Elise Aasebø,Håkon Reikvam,Øystein Bruserud,Maria Hernandez-Valladares

DOI: https://doi.org/10.3390/ijms25105080

IF: 5.6

2024-05-07

International Journal of Molecular Sciences

Abstract:Even though morphological signs of differentiation have a minimal impact on survival after intensive cytotoxic therapy for acute myeloid leukemia (AML), monocytic AML cell differentiation (i.e., classified as French/American/British (FAB) subtypes M4/M5) is associated with a different responsiveness both to Bcl-2 inhibition (decreased responsiveness) and possibly also bromodomain inhibition (increased responsiveness). FAB-M4/M5 patients are heterogeneous with regard to genetic abnormalities, even though monocytic differentiation is common for patients with Nucleophosmin 1 (NPM1) insertions/mutations; to further study the heterogeneity of FAB-M4/M5 patients we did a proteomic and phosphoproteomic comparison of FAB-M4/M5 patients with (n = 13) and without (n = 12) NPM1 mutations. The proteomic profile of NPM1-mutated FAB-M4/M5 patients was characterized by increased levels of proteins involved in the regulation of endocytosis/vesicle trafficking/organellar communication. In contrast, AML cells without NPM1 mutations were characterized by increased levels of several proteins involved in the regulation of cytoplasmic translation, including a large number of ribosomal proteins. The phosphoproteomic differences between the two groups were less extensive but reflected similar differences. To conclude, even though FAB classification/monocytic differentiation are associated with differences in responsiveness to new targeted therapies (e.g., Bcl-2 inhibition), our results shows that FAB-M4/M5 patients are heterogeneous with regard to important biological characteristics of the leukemic cells.

biochemistry & molecular biology,chemistry, multidisciplinary
Bioinformatics and Raman spectroscopy-based identification of key pathways and genes enabling differentiation between acute myeloid leukemia and T cell acute lymphoblastic leukemia

Haoyue Liang,Xiaodong Kong,Zhijie Cao,Haoyu Wang,Ertao Liu,Fanfan Sun,Jianwei Qi,Qiang Zhang,Yuan Zhou

DOI: https://doi.org/10.3389/fimmu.2023.1194353

IF: 7.3

2023-05-17

Frontiers in Immunology

Abstract:Acute myeloid leukemia (AML) and T cell acute lymphoblastic leukemia (T-ALL) are two of the most prevalent hematological malignancies diagnosed among adult leukemia patients, with both being difficult to treat and associated with high rates of recurrence and mortality. In the present study, bioinformatics approaches were used to analyze both of these types of leukemia in an effort to identify characteristic gene expression patterns that were subsequently validated via Raman spectroscopy. For these analyses, four Gene Expression Omnibus datasets (GSE13204, GSE51082, GSE89565, and GSE131184) pertaining to acute leukemia were downloaded, and differentially expressed genes (DEGs) were then identified through comparisons of AML and T-ALL patient samples using the R Bioconductor package. Shared DEGs were then subjected to Gene Ontology (GO) enrichment analyses and were used to establish a protein-protein interaction (PPI) network analysis. In total, 43 and 129 upregulated and downregulated DEGs were respectively identified. Enrichment analyses indicated that these DEGs were closely tied to immune function, collagen synthesis and decomposition, inflammation, the synthesis and decomposition of lipopolysaccharide, and antigen presentation. PPI network module clustering analyses further led to the identification of the top 10 significantly upregulated and downregulated genes associated with disease incidence. These key genes were then validated in patient samples via Raman spectroscopy, ultimately confirming the value of these genes as tools that may aid the differential diagnosis and treatment of AML and T-ALL. Overall, these results thus highlight a range of novel pathways and genes that are linked to the incidence and progression of AML and T-ALL, providing a list of important diagnostic and prognostic molecular markers that have the potential to aid in the clinical diagnosis and treatment of these devastating malignancies.

immunology
Microbial metabolomics in acute myeloid leukemia: From pathogenesis to treatment

Aneta Nowicka,Lidia Gil

DOI: https://doi.org/10.17219/acem/191559

2024-10-21

Abstract:Acute myeloid leukemia (AML), the most common leukemia in adults, is a biologically heterogeneous disease arising from clonally proliferating hematopoietic stem cells. Increased appreciation of novel genetic methods has improved the understanding of AML biology. Recently, the emerging field of metabolomics has indicated qualitative and quantitative alterations in metabolic profiles in AML pathogenesis, progression and treatment. Multiple metabolic and molecular pathways regulate human metabolism and host-microbiome interactions may significantly affect this biochemical machinery. Microbiota have been found to play a significant role in hematopoietic function, metabolism and immunity, contributing to AML occurrence. A large number of studies have highlighted the importance of the composition and diversity of the gut microbiota (GM) in response to treatment and prognosis in AML. Moreover, strong evidence emphasizes the detrimental link between dysbiosis and infectious complications, a leading cause of morbidity and mortality for patients with AML. Several microbiota-related mechanisms have been linked to particular changes in host physiology so far, and microbial-derived metabolites belong to one of the most important. Circulating in the body, they modulate human conditions both locally and systemically. The extensive and diverse repertoire of bacterial metabolic functions plays a critical role in numerous processes, including leukemogenesis. Integrative analysis of microbiome and metabolome data is a promising avenue for better understanding the complex relationship between the microbiota, biochemical alterations and AML pathogenesis to effectively prevent, treat and mitigate its outcomes. This review concentrates on the pathologic roles and therapeutic implications of microbe-derived metabolites in AML settings.
Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion

Jingqun Ma,Yen-Chun Liu,Rebecca K. Voss,Jing Ma,Ajay Palagani,Elizabeth Caldwell,Wojciech Rosikiewicz,Maria Cardenas,Scott Foy,Masayuki Umeda,Mark R. Wilkinson,Hiroto Inaba,Jeffery M. Klco,Jeffrey E. Rubnitz,Lu Wang

DOI: https://doi.org/10.1038/s41375-024-02194-x

2024-03-02

Leukemia

Abstract:PICALM::MLLT10 fusion is a rare but recurrent genetic driver in acute leukemias. To better understand the genomic landscape of PICALM::MLLT10 (PM) positive acute leukemia, we performed genomic profiling and gene expression profiling in twenty PM-positive patients, including AML ( n = 10), T-ALL/LLy ( n = 8), Mixed-phenotype acute leukemia (MPAL), T/B ( n = 1) and acute undifferentiated leukemia (AUL) ( n = 1). Besides confirming the known activation of HOXA, differential gene expression analysis compared to hematopoietic stem cells demonstrated the enrichment of genes associated with cell proliferation-related pathways and relatively high expression of XPO1 in PM-AML and PM-T-ALL/LLy. Our study also suggested PHF6 disruption as a key cooperating event in PICALM::MLLT10-positive leukemias. In addition, we demonstrated differences in gene expression profiles as well as remarkably different spectra of co-occurring mutations between PM-AML and PM-T-ALL/LLy. Alterations affecting TP53 and NF1, hallmarks of PM-AML, are strongly associated with disease progression and relapse, whereas EZH2 alterations are highly enriched in PM-T-ALL/LLy. This comprehensive genomic and transcriptomic profiling provides insights into the pathogenesis and development of PICALM::MLLT10 positive acute leukemia.

oncology,hematology
Comprehensive proteomic analysis of murine terminal erythroid differentiation.

M. Fontenay,F. Guillonneau,Ismael Boussaid,F. Verdier,P. Mayeux,C. Lefèvre,N. Mohandas,C. Hillyer,M. Ladli,Emilie-Fleur Gautier,C. Lacombe,M. Leduc,Vincent P. Schulz,P. Gallagher

DOI: https://doi.org/10.1182/bloodadvances.2020001652

IF: 7.642

2020-04-13

Blood Advances

Abstract:Murine-based cellular models have provided and continue to provide many useful insights into the fundamental mechanisms of erythropoiesis, as well as insights into the pathophysiology of inherited and acquired red cell disorders. Although detailed information on many aspects of these cell models is available, comprehensive proteomic data are lacking. This is a critical knowledge gap, as proteins are effectors of most biologic processes. To address this critical unmet need, proteomes of the murine cell lines Friend erythroleukemia (MEL), GATA1 erythroid (G1ER), and embryonic stem cell-derived erythroid progenitor (MEDEP) and proteomes of cultured murine marrow-derived erythroblasts at different stages of terminal erythroid differentiation were analyzed. The proteomes of MEDEP cells and primary murine erythroid cells were most similar, whereas those of MEL and G1ER cells were more distantly related. We demonstrated that the overall cellular content of histones does not decrease during terminal differentiation, despite strong chromatin condensation. Comparison of murine and human proteomes throughout terminal erythroid differentiation revealed that many noted transcriptomic changes were significantly dampened at the proteome level, especially at the end of the terminal differentiation process. Analysis of the early events associated with induction of terminal differentiation in MEDEP cells revealed divergent alterations in associated transcriptomes and proteomes. These proteomic data are powerful and valuable tools for the study of fundamental mechanisms of normal and disordered erythropoiesis and will be of broad interest to a wide range of investigators for making the appropriate choice of various cell lines to study inherited and acquired diseases of the erythrocyte.

Medicine,Biology
Adaptive immunity-related gene expression profile is correlated with clinical phenotype in patients with acute myeloid leukemia

Peng Chen,Yi Liu,Rui Zhang,Haitao Wang,Juan Zhang,Meng Guo,Zhenlan Du

DOI: https://doi.org/10.21037/atm-21-2720

IF: 3.616

2021-06-01

Annals of Translational Medicine

Abstract:BACKGROUND: Acute myeloid leukemia (AML) is a common and lethal hematopoietic malignancy that is highly dependent on the immune microenvironment. However, light has yet to be shed on the landscape of adaptive immunity-related genes. This work aimed to uncover the novel molecular events in AML and potential therapeutic strategies for AML treatment.METHODS: For the current research, the transcriptional information of 732 genes that participate in adaptive immunity was collected from 173 patients with AML, and the patients were grouped into different cohorts based on the different expression patterns. The correlations between gene expression and clinical characteristics, including prognosis, were studied.RESULTS: According to the notably different expressions of adaptive immunity-related genes, the 173 patients were divided into 2 clusters and 3 subclusters. No significant differences in overall survival (OS) or progression-free survival (PFS) were detected between the clusters or subclusters. There were obvious discrepancies found in age, peripheral blood (PB) blast percentage, and French-American-British (FAB) classification between each cluster or subcluster. The patients in cluster 1 were older and more of them had M5 type; the patients in cluster 2 were younger and more of them had M2 type. Further, 81 genes were significantly correlated with age and 101 genes were significantly correlated with PB blast percentage. Comparison of the prognosis between each FAB type revealed that patients with M3 type displayed the most favorable OS and PFS. Among the differentially expressed genes (DEGs), CLEC2B expression was much lower in M2 patients than in patients with other types (P<0.001), and its high expression indicated a worse outcome (12.4 <i>vs.</i> 46.5 months of OS).CONCLUSIONS: This study has uncovered the expression profile of adaptive immunity-related genes in AML. The different gene expression patterns are not associated with survival, but are significantly correlated the FAB types. CLEC2B expression is low in patients with M2 type and is negatively correlated with prognosis, thus revealing a potential therapeutic target for AML.

oncology,medicine, research & experimental
Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children

Svea Stratmann,Mattias Vesterlund,Husen M. Umer,Saeed Eshtad,Aron Skaftason,Morten Krogh Herlin,Christer Sundström,Anna Eriksson,Martin Höglund,Josefine Palle,Jonas Abrahamsson,Kirsi Jahnukainen,Monica Cheng Munthe-Kaas,Bernward Zeller,Katja Pokrovskaja Tamm,Cecilia Lindskog,Lucia Cavelier,Janne Lehtiö,Linda Holmfeldt

DOI: https://doi.org/10.1038/s41375-022-01796-7

2022-12-27

Leukemia

Abstract:Despite improvement of current treatment strategies and novel targeted drugs, relapse and treatment resistance largely determine the outcome for acute myeloid leukemia (AML) patients. To identify the underlying molecular characteristics, numerous studies have been aimed to decipher the genomic- and transcriptomic landscape of AML. Nevertheless, further molecular changes allowing malignant cells to escape treatment remain to be elucidated. Mass spectrometry is a powerful tool enabling detailed insights into proteomic changes that could explain AML relapse and resistance. Here, we investigated AML samples from 47 adult and 22 pediatric patients at serial time-points during disease progression using mass spectrometry-based in-depth proteomics. We show that the proteomic profile at relapse is enriched for mitochondrial ribosomal proteins and subunits of the respiratory chain complex, indicative of reprogrammed energy metabolism from diagnosis to relapse. Further, higher levels of granzymes and lower levels of the anti-inflammatory protein CR1/CD35 suggest an inflammatory signature promoting disease progression. Finally, through a proteogenomic approach, we detected novel peptides, which present a promising repertoire in the search for biomarkers and tumor-specific druggable targets. Altogether, this study highlights the importance of proteomic studies in holistic approaches to improve treatment and survival of AML patients.

oncology,hematology
In silico analysis of genes and pathways related to acute myeloid leukemia presenting leukopenia

Ajeet Kumar,Ravi Bhushan,Pawan K. Dubey,Vijai Tilak,Vineeta Gupta,Nilesh Kumar,S.V.S Raju,Akhtar Ali

DOI: https://doi.org/10.21203/rs.3.rs-1019863/v1

2021-11-17

Abstract:Abstract Acute myeloid leukemia (AML) is a type of blood cancers that begins from progenitor and hematopoietic stem cell. Chromosomal abnormalities include balanced translocations between two chromosome like t[8;21] and t[15;17]) in malignancies cells. The present study aimed to explore the AML presenting with leukopenia and gene expression changes induced in High-white count B-cell and Low-white count B-cell the total number of samples is ten. The raw gene expression profiles (ID: GSE20482) of bone marrow achieve from AML patient five High-white count B-cell and five Low-white count B-cell were expressed genes used to recognize differentially. These genes that correspond to official gene symbols were select for protein-protein interaction (PPI) and sub-network construction (score > 0.4). The functional annotation of Gene Ontology (GO) and pathways analysis were performed for those genes involve in networking. Results The total number of 846 genes were identified differentially expressed gene and 406 gene were up-regulated another 440 gene were down-regulated. Other 14 genes are interacting with each other significantly identified. Including Hub genes DEGs GNB4, LAMTOR2, ACTN4, HGSNAT, TMED1 are up-regulated while down-regulated DEGs forming hub nodes were UBR4, FBXO30, KLHL21, DCTN6, RNF123, RNF114. AML has a major effect on the expression of genes involved in cell differentiation, apoptosis, cell signaling and modification of protein. AML cells enter the blood quickly and spread to the liver, spleen, and central nervous system. These are total thirteen pathways were enriched and these genes related to oxidative phosphorylation, regulation of actin cytoskeleton, endocytosis, phagocytosis, shigellosis, epithelial cell signaling in helicobacter, adherent junction, pertussis, bile secretion, malaria, African trypanosomiasis were found significantly affected by AML. Conclusions Hub genes like GNB4 and UBR4 provide as a novel biomarker in AML.
A single-cell survey of cellular hierarchy in acute myeloid leukemia

Junqing Wu,Yanyu Xiao,Jie Sun,Huiyu Sun,Haide Chen,Yuanyuan Zhu,Huarui Fu,Chengxuan Yu,Weigao E.,Shujing Lai,Lifeng Ma,Jiaqi Li,Lijiang Fei,Mengmeng Jiang,Jingjing Wang,Fang Ye,Renying Wang,Ziming Zhou,Guodong Zhang,Tingyue Zhang,Qiong Ding,Zou Wang,Sheng Hao,Lizhen Liu,Weiyan Zheng,Jingsong He,Weijia Huang,Yungui Wang,Jin Xie,Tiefeng Li,Tao Cheng,Xiaoping Han,He Huang,Guoji Guo

DOI: https://doi.org/10.1186/s13045-020-00941-y

2020-09-25

Abstract:Abstract Background Acute myeloid leukemia (AML) is a fatal hematopoietic malignancy and has a prognosis that varies with its genetic complexity. However, there has been no appropriate integrative analysis on the hierarchy of different AML subtypes. Methods Using Microwell-seq, a high-throughput single-cell mRNA sequencing platform, we analyzed the cellular hierarchy of bone marrow samples from 40 patients and 3 healthy donors. We also used single-cell single-molecule real-time (SMRT) sequencing to investigate the clonal heterogeneity of AML cells. Results From the integrative analysis of 191727 AML cells, we established a single-cell AML landscape and identified an AML progenitor cell cluster with novel AML markers. Patients with ribosomal protein high progenitor cells had a low remission rate. We deduced two types of AML with diverse clinical outcomes. We traced mitochondrial mutations in the AML landscape by combining Microwell-seq with SMRT sequencing. We propose the existence of a phenotypic “cancer attractor” that might help to define a common phenotype for AML progenitor cells. Finally, we explored the potential drug targets by making comparisons between the AML landscape and the Human Cell Landscape. Conclusions We identified a key AML progenitor cell cluster. A high ribosomal protein gene level indicates the poor prognosis. We deduced two types of AML and explored the potential drug targets. Our results suggest the existence of a cancer attractor.

oncology,hematology

Comparative proteome analysis of acute myeloid leukemia with and without maturation.

[Analysis of Age-Specific Cytogenetic Changes among 515 Patients Withacute Myeloid Leukemia].

Aging and Comprehensive Molecular Profiling in Acute Myeloid Leukemia.

MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Clinical and Biological Characteristics of Acute Myeloid Leukemia with 20-29% Blasts: a Retrospective Single-Center Study

Clinical Characterization and Prognostic Factors of 144 Adult Acute Monocytic Leukemia

Proteomic Analysis of Human Acute Leukemia Cells

Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy

Analysis of the Proteomes of Primary, De Novo Acute Myeloid Leukemia Cells from Adults

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia

Abstract 7354: Proteogenomic and metabolomic characterization of acute myeloid leukemia

Abstract P27: Proteogenomic and metabolomic analysis of acute myeloid leukemia reveals molecular and functional underpinnings of cellular and clinical phenotypes

A Proteomic and Phosphoproteomic Comparison of FAB-M4/M5 Patients with and without Nucleophosmin 1 Mutations

Bioinformatics and Raman spectroscopy-based identification of key pathways and genes enabling differentiation between acute myeloid leukemia and T cell acute lymphoblastic leukemia

Microbial metabolomics in acute myeloid leukemia: From pathogenesis to treatment

Genomic and global gene expression profiling in pediatric and young adult acute leukemia with PICALM::MLLT10 Fusion

Comprehensive proteomic analysis of murine terminal erythroid differentiation.

Adaptive immunity-related gene expression profile is correlated with clinical phenotype in patients with acute myeloid leukemia

Proteogenomic analysis of acute myeloid leukemia associates relapsed disease with reprogrammed energy metabolism both in adults and children

In silico analysis of genes and pathways related to acute myeloid leukemia presenting leukopenia

A single-cell survey of cellular hierarchy in acute myeloid leukemia